---

COPD - Clinical Medicine Guide for Final Year Practicals

---

1. Definition

---

2. Epidemiology & Risk Factors

• 3rd most common cause of death in the United States
• Cigarette smoking is by far the major risk factor (most important)
• Only 15-30% of habitual smokers were historically thought to develop COPD, but radiographic studies now show progressive bronchial wall thickening and lung tissue loss even in smokers with normal spirometry
• Other risk factors: occupational dust/fumes, air pollution, alpha-1 antitrypsin (AAT) deficiency, recurrent respiratory infections

---

3. The Two Clinical Phenotypes: "Pink Puffer" vs. "Blue Bloater"

---

4. Pathology

Emphysema

• Enlargement of air spaces distal to terminal bronchioles caused by destruction of alveolar walls by proteases (especially from neutrophils)
• Centriacinar (centrilobular) - most common type; smoking-related; upper lobe predominant
• Panacinar (panlobular) - seen in alpha-1 antitrypsin deficiency; lower lobe predominant
• Loss of elastic recoil leads to airway collapse on expiration - the key mechanism of obstruction
• Marked by increased chest volume, dyspnea, relatively normal blood oxygenation at rest

Chronic Bronchitis

• Clinical definition: productive cough for at least 3 consecutive months in at least 2 consecutive years (must exclude other causes)
• Mucus hypersecretion from hyperplasia of tracheobronchial mucous glands
• Airway obstruction is from small airway inflammation (chronic bronchiolitis), not the large airway gland hyperplasia
• Histology: Reid index (mucous gland thickness / total wall thickness) is increased (>0.4)
• Goblet cell metaplasia, airway wall inflammation, bronchiolar wall fibrosis

---

5. Pathophysiology

Mechanism of Airflow Obstruction

1. Reduced elastic recoil (emphysema) - airways collapse during expiration
2. Airway inflammation and fibrosis (bronchitis) - fixed narrowing
3. Mucus hypersecretion - luminal occlusion
4. Air trapping and dynamic hyperinflation

Gas Exchange Abnormalities

• V/Q mismatch is the primary mechanism of hypoxemia
• PaCO2 doesn't usually rise until FEV1 falls to about 20-25% of predicted
• In severe disease: hypoxemia and hypercapnia develop

Dynamic Hyperinflation (high-yield for viva)

• Increased ventilatory demand during exercise + insufficient expiratory time → air trapping
• End-expiratory lung volume (EELV) fails to return to normal
• Diaphragm is flattened → loses mechanical advantage → paradoxical inward movement during inspiration
• Causes: increased total lung capacity (TLC), increased functional residual capacity (FRC), increased residual volume (RV)
• Results in: dyspnea, exercise intolerance, increased work of breathing

---

6. Clinical Features

Symptoms

• Progressive exertional dyspnea - the hallmark symptom
• Chronic productive cough - morning cough with sputum
• Wheeze
• Symptoms worsen gradually over years; often ignored until severe

Signs on Examination (with likelihood ratios - Symptom to Diagnosis, p. 2221)

Typical Examination Findings

• Inspection: barrel chest (increased AP diameter), use of accessory muscles, pursed-lip breathing, intercostal recession, tracheal descent on inspiration
• Palpation: reduced chest expansion, trachea may be central, tactile fremitus reduced
• Percussion: hyperresonance, reduced cardiac and hepatic dullness, low flat diaphragms
• Auscultation: reduced air entry, prolonged expiration, wheeze, early inspiratory crackles

---

7. Spirometry and GOLD Classification

GOLD Severity Grading (based on FEV1 % predicted, after meeting FEV1/FVC < 0.7):

Full PFT Pattern in COPD:

• FEV1 ↓↓
• FVC ↓ (or normal)
• FEV1/FVC ratio ↓ (< 0.70) - obstructive pattern
• TLC ↑ (due to reduced elastic recoil)
• RV ↑ (air trapping)
• FRC ↑
• DLCO ↓ (destruction of alveolar-capillary interface, especially in emphysema)

---

8. Investigations

---

9. Management

Step 1: Non-pharmacological (Always)

• Smoking cessation - the single most important intervention; slows disease progression
• Pulmonary rehabilitation - improves exercise tolerance and QoL
• Vaccinations: influenza (annual), pneumococcal, COVID-19
• Nutritional support
• Oxygen therapy if PaO2 < 55 mmHg (or < 60 mmHg with cor pulmonale/polycythemia) - Long-term oxygen therapy (LTOT) for ≥ 15 hours/day

Step 2: Pharmacological - Stable COPD

Step 3: Surgical Options

• Lung volume reduction surgery (LVRS) - for upper-lobe-predominant emphysema
• Endobronchial valves (bronchoscopic lung volume reduction)
• Lung transplantation - end-stage disease

---

10. Acute Exacerbations of COPD (AECOPD)

Management of AECOPD:

1. Controlled oxygen - target SaO2 88-92% (NOT high-flow; risk of hypercapnic drive suppression)
2. Bronchodilators - nebulised salbutamol + ipratropium
3. Systemic corticosteroids - prednisolone 30-40 mg for 5-7 days (shorten attack duration)
4. Antibiotics - if purulent sputum, increased dyspnea, or increased sputum volume (Anthonisen criteria). Use amoxicillin/doxycycline/azithromycin; beta-lactams for H. influenzae
5. NIV (Non-invasive ventilation) - if hypercapnic respiratory failure (pH < 7.35, PaCO2 > 6 kPa). Reduces need for intubation and mortality
6. Invasive ventilation - if NIV fails or contraindicated

---

11. Complications

• Cor pulmonale - right heart failure from pulmonary hypertension (chronic hypoxia causes pulmonary vasoconstriction)
• Polycythemia - secondary to chronic hypoxia, increases thrombosis risk
• Spontaneous pneumothorax - from ruptured bullae
• Respiratory failure - hypoxic and/or hypercapnic
• Lung cancer - increased risk (common risk factor: smoking)
• Pulmonary hypertension
• Depression and anxiety - commonly under-recognised

---

12. Clinical Case Scenario (Exam-Style Viva)

• FEV1/FVC < 0.70 confirms obstructive pattern
• PaO2 of 60 mmHg is markedly reduced (normal 100 mmHg)
• PaCO2 of 30 mmHg is low - patient is hyperventilating due to hypoxic drive stimulating peripheral chemoreceptors
• pH 7.47 - mild respiratory alkalosis from hyperventilation
• A-a gradient is increased (calculated PAO2 ≈ 113 mmHg vs. measured PaO2 = 60 mmHg) - confirms V/Q mismatch
• FEV1 60% predicted = GOLD Grade 2 (Moderate)
• Barrel chest = compensatory mechanism to increase FRC and reduce work of breathing

---

13. Key Differentials

---

14. High-Yield Points for Practicals & Viva

1. Diagnosis requires spirometry - FEV1/FVC < 0.70 post-bronchodilator
2. Chronic bronchitis is a CLINICAL diagnosis - 3 months x 2 consecutive years
3. Pink puffer vs. blue bloater - know the table cold
4. AAT deficiency - suspect in young, non-smoker; panacinar emphysema, lower lobes
5. Controlled O2 in AECOPD - target 88-92%, not 100%
6. NIV indication - pH < 7.35 + hypercapnia; reduces mortality
7. ICS - do NOT use alone in COPD; use eosinophil count to guide
8. Smoking cessation - the only intervention proven to slow FEV1 decline
9. LTOT - prescribed when PaO2 ≤ 55 mmHg; must use ≥ 15 h/day to reduce mortality
10. Cor pulmonale - right heart failure secondary to pulmonary hypertension from hypoxia

---

---

COPD - Complete Long Case for Final Year Practicals

---

PART 1: THE CASE PRESENTATION

---

PRESENTING COMPLAINT

• Worsening breathlessness for the past 4 days
• Increased cough with yellowish-green sputum
• Bilateral ankle swelling for 2 weeks

---

HISTORY OF PRESENTING COMPLAINT

---

SYSTEMATIC ENQUIRY

• Cardiovascular: Bilateral ankle oedema, no chest pain, no palpitations. Note: 30% of COPD patients have significant cardiovascular comorbidities.
• Gastrointestinal: Poor appetite and weight loss of 5 kg over 6 months (may suggest malignancy - must exclude).
• Neurological: No headaches, no tremors. Ask about morning headache (suggests nocturnal hypercapnia).
• Sleep: Excessive daytime somnolence, snoring (consider OSA overlap - "overlap syndrome").

---

PAST MEDICAL HISTORY

• Diagnosed with COPD 6 years ago
• Two hospital admissions for "chest infections" - one requiring ICU stay
• Hypertension (on amlodipine)
• No previous TB, no diabetes

---

DRUG HISTORY

• Salbutamol (SABA) inhaler - uses 6-8 puffs/day (suggests poor control)
• Tiotropium (LAMA) - once daily
• Seretide (fluticasone + salmeterol) 500 mcg - twice daily
• Amlodipine 10 mg OD
• Aspirin 75 mg OD

---

FAMILY HISTORY

• Father died of "lung disease" - smoking history unknown
• (Always ask about AAT deficiency if onset is young or non-smoker)

---

SOCIAL HISTORY

• Smoking: 40 pack-year history (20 cigarettes/day x 40 years). Still smoking.
• Alcohol: 14 units/week
• Occupation: Retired construction worker (occupational dust/asbestos exposure possible)
• Housing: Lives in a ground-floor flat with his wife. Has not been able to leave the house for the past 3 months.
• ADLs: Dependent on wife for most activities of daily living.
• Exercise tolerance: Currently limited to walking to the toilet.
• Vaccinations: Not up to date (missed last flu vaccine).

---

PART 2: EXAMINATION

---

GENERAL INSPECTION (Begin here - examiner watches everything)

• Tripod position (bracing arms to recruit accessory muscles)
• Central cyanosis (blue lips and tongue)
• Cachexia / muscle wasting
• Pursed-lip breathing (helps prevent small airway collapse by generating positive end-expiratory pressure)
• Peripheral oedema visible

---

VITAL SIGNS

---

HANDS

• Tar staining (nicotine staining on fingers) - smoking history
• Peripheral cyanosis - bluish discolouration of nail beds
• Finger clubbing - NOT a feature of COPD; if present, must exclude lung cancer, bronchiectasis, or interstitial fibrosis. (High-yield: absence of clubbing helps distinguish from these.)
• Asterixis (liver flap) - assess for CO2 retention (flapping tremor when wrists extended)
• Fine tremor (salbutamol side effect)
• Wasting of small muscles (cachexia)

---

FACE AND NECK

• Central cyanosis: Blue lips and tongue - examine mucous membranes
• Conjunctival pallor: Check for anaemia (can worsen dyspnoea)
• Pursed-lip breathing
• Jugular venous pressure (JVP): Raised in cor pulmonale / right heart failure - look for hepatojugular reflux
• Facial plethora (polycythemia)

---

RESPIRATORY SYSTEM

Inspection

• Barrel chest - increased AP diameter due to hyperinflation (AP:transverse ratio approaches 1:1; normally 1:2)
• Use of accessory muscles: Sternocleidomastoid, scalenes
• Intercostal recession
• Tracheal descent on inspiration (Hoover's sign of hyperinflation)
• Symmetrical chest movement (if asymmetrical, consider pneumothorax or consolidation)

Palpation

• Trachea: Central (deviation suggests pneumothorax or consolidation)
• Chest expansion: Bilaterally reduced
• Tactile fremitus: Reduced throughout (hyperinflation attenuates transmission)
• Apex beat: Displaced downward and laterally (or impalpable due to hyperinflation) - note subxiphoid cardiac impulse if right ventricular heave

Percussion

• Bilateral hyperresonance throughout
• Liver dullness pushed down (hyperinflated lungs push liver inferiorly)
• Absent cardiac dullness (specificity 99% for COPD - LR+ 15)
• Diaphragmatic excursion < 2 cm (specificity 98%, LR+ 6.5)

Auscultation

• Globally reduced air entry bilaterally
• Prolonged expiratory phase (I:E ratio reversed; normally 1:2, in COPD may be 1:4 or more)
• Wheeze (polyphonic, bilateral, expiratory - airflow obstruction)
• Early inspiratory crackles (specificity 97-98%, LR+ 8-38.5 for COPD - Symptom to Diagnosis, 4th Ed.)
• Note: absence of wheeze does NOT rule out COPD

---

CARDIOVASCULAR SYSTEM

• JVP raised (cor pulmonale, right heart failure)
• Right ventricular heave (left parasternal heave - RV enlargement from pulmonary hypertension)
• Loud P2 (pulmonary hypertension)
• TR murmur (tricuspid regurgitation from RV dilatation - pansystolic at lower left sternal border, increases with inspiration - Carvallo's sign)
• Pitting pedal oedema: Bilateral, pitting, extending to mid-shin

---

ABDOMINAL EXAMINATION

• Hepatomegaly: Tender, pulsatile (if TR present); or tender from hepatic congestion in right heart failure
• Shifting dullness / fluid thrill: Ascites in severe cor pulmonale
• No splenomegaly expected

---

SUMMARY OF FINDINGS

---

PART 3: INVESTIGATIONS

---

BEDSIDE

---

ARTERIAL BLOOD GAS (ABG) - HIGH YIELD

• Acute change (pH drop) on top of chronic compensated hypercapnia (elevated HCO3) = acute-on-chronic CO2 retention
• The elevated bicarbonate tells you the hypercapnia is NOT new - the kidneys have had time to retain HCO3 (takes 2-5 days)

---

BLOOD TESTS

---

SPIROMETRY (Gold Standard for Diagnosis)

---

IMAGING

• Low attenuation areas = emphysema
• Airway wall thickening = chronic bronchitis
• Upper lobe predominant = centrilobular (smoking)
• Lower lobe predominant = panacinar (AAT deficiency)
• Can detect bullae, bronchiectasis, lung cancer

---

PART 4: DIAGNOSIS

---

PRIMARY DIAGNOSIS

SECONDARY DIAGNOSES

1. Type 2 Respiratory Failure - acute-on-chronic
2. Cor Pulmonale (right heart failure secondary to pulmonary hypertension from chronic hypoxia)
3. Infective Exacerbation (likely bacterial - purulent sputum)

---

DIFFERENTIAL DIAGNOSES TO EXCLUDE

---

PART 5: MANAGEMENT

---

IMMEDIATE (First 1-2 Hours)

• Target SpO2 88-92% (NOT 94-98% as in other patients)
• Rationale: Hypoxic drive is important in some COPD patients with chronic CO2 retention; high-flow O2 can worsen hypercapnia through ventilation-perfusion mismatch worsening and Haldane effect
• Use Venturi mask at 24% (2L) or 28% (4L) - titrate to target
• Re-check ABG 30-60 minutes after starting O2

• Nebulised salbutamol 2.5 mg every 1-4 hours
• Add nebulised ipratropium 0.5 mg every 4 hours if inadequate response
• Driven by oxygen or air (not air if hypoxic - use O2 to drive nebuliser but limit flow to 6 L/min)

• Prednisolone 40 mg orally for 5 days (Washington Manual, p. 4943)
• If nil by mouth: IV hydrocortisone 100 mg TDS
• Reduces recovery time, treatment failure, and length of stay

• No risk factors: Amoxicillin 500 mg TDS, or doxycycline 200 mg loading then 100 mg OD, or azithromycin 500 mg OD
• Risk factors present (age >65, FEV1 <50%, >3 exacerbations/year, cardiac comorbidity, recent antibiotics): Antipseudomonal fluoroquinolone (ciprofloxacin) or antipseudomonal beta-lactam
• Treat for 5-7 days

---

NON-INVASIVE VENTILATION (NIV) - CRITICAL DECISION

• pH < 7.35 AND PaCO2 elevated (hypercapnic respiratory failure)
• RR > 25/min despite maximal medical therapy
• Persistent hypoxaemia despite controlled O2

• IPAP: 12-20 cmH2O
• EPAP: 4-6 cmH2O

---

CRITERIA FOR ICU ADMISSION (Washington Manual)

• Need for invasive mechanical ventilation
• Haemodynamic instability
• Severe dyspnoea not responding to NIV/therapy
• Mental status changes
• Persistent/worsening hypoxaemia, hypercapnia, or acidosis despite NIV

---

MANAGEMENT OF COR PULMONALE / RIGHT HEART FAILURE

• The primary treatment is treating the underlying COPD and correcting hypoxia
• Long-term oxygen therapy (LTOT): prescribed when PaO2 ≤ 55 mmHg (or ≤ 60 mmHg with cor pulmonale or polycythaemia) - must use ≥ 15 hours/day
• Diuretics (furosemide) for oedema
• DO NOT use ACE inhibitors or beta-blockers indiscriminately (can worsen bronchospasm)

---

SUBSEQUENT MANAGEMENT (Inpatient Days 2-7)

1. Step down to oral bronchodilators when improving
2. Physiotherapy - sputum clearance, breathing exercises
3. Smoking cessation counselling (urgent - most impactful intervention)
4. Nutritional support (cachexia worsens muscle function and prognosis)
5. Spirometry to confirm diagnosis (when stable)
6. Review inhaler technique and devices
7. Consider LTOT assessment if PaO2 remains low when stable (ABG at 4-6 weeks post-exacerbation)

---

DISCHARGE CRITERIA

• Nebulised bronchodilators not required more than every 4 hours
• Patient (or carer) able to use inhalers correctly
• Stable on inhaled therapy for 12-24 hours
• No further deterioration of ABG
• Adequate home support

---

DISCHARGE PRESCRIPTION (Step-up from Admission)

• ICS + LABA + LAMA (triple therapy) - e.g., Trimbow or Trelegy
• Rescue SABA PRN
• Consider roflumilast if FEV1 < 50% + chronic bronchitis phenotype + ≥ 2 exacerbations/year
• Prophylactic azithromycin 250 mg 3x/week (if non-smoker; not given to current smokers due to QT risks and NTM risk)

---

PART 6: COMPLICATIONS & PROGNOSIS

---

Complications

---

Prognosis - BODE Index (Multidimensional Grading)

---

PART 7: VIVA QUESTIONS & MODEL ANSWERS

---

Controlled oxygen via Venturi mask targeting SpO2 88-92%, and arrange an ABG urgently.

In patients with chronic CO2 retention, high-flow oxygen can worsen hypercapnia through three mechanisms: (1) V/Q mismatch worsening (oxygen reverses hypoxic vasoconstriction, diverting blood to poorly ventilated units), (2) Haldane effect (oxyhaemoglobin reduces CO2-carrying capacity of blood), and (3) reduced hypoxic respiratory drive (minor contribution but relevant in a subset of patients).

Productive cough for at least 3 consecutive months in at least 2 consecutive years, after excluding other causes. This is a clinical definition.

Type 1 = hypoxaemia (PaO2 < 8 kPa) without hypercapnia - due to V/Q mismatch or shunting. Type 2 = hypoxaemia AND hypercapnia (PaCO2 > 6 kPa) - due to ventilatory pump failure or hypoventilation. COPD can cause both, but severe COPD with muscle fatigue and dynamic hyperinflation typically causes type 2.

If NIV fails to improve pH, if the patient cannot protect their airway, if GCS < 8, if there is haemodynamic instability, or if there are absolute contraindications to NIV (vomiting, facial trauma, recent upper GI surgery).

Right ventricular hypertrophy and eventual failure caused by pulmonary hypertension due to primary lung or pulmonary vascular disease. In COPD, chronic hypoxia causes sustained hypoxic pulmonary vasoconstriction → increased pulmonary vascular resistance → pulmonary hypertension → right ventricular pressure overload. Overt right heart failure with decreased cardiac output occurs late in the course. Signs: raised JVP, RV heave, loud P2, TR murmur, peripheral oedema, hepatomegaly. (Fuster and Hurst's The Heart, 15th Ed.)

Alpha-1 antitrypsin is a protease inhibitor that normally inactivates neutrophil elastase. Deficiency leads to unopposed elastase activity → panacinar emphysema predominantly affecting the lower lobes. Suspect when: COPD onset < 45 years, non-smoker or minimal smoking history, family history, lower lobe predominant emphysema on CT, or concurrent liver disease. The ATS recommends testing all patients with persistent airflow obstruction.

COPD does not cause clubbing. If present, it is a red flag to actively exclude lung cancer, bronchiectasis, interstitial pulmonary fibrosis, or mesothelioma - conditions that share risk factors (smoking, occupational exposure) with COPD.

NIV (BiPAP) provides inspiratory pressure support that augments tidal volume and reduces work of breathing, and PEEP that prevents small airway collapse. Together they improve alveolar ventilation, reduce CO2, and correct acidosis. It avoids complications of intubation. Evidence shows it reduces mortality, intubation rates, and ICU length of stay.

BODE is a multidimensional tool incorporating BMI, airflow Obstruction (FEV1), Dyspnoea (mMRC scale), and Exercise capacity (6-minute walk test). It better predicts mortality than FEV1 alone because COPD is a systemic disease with nutritional, functional, and symptomatic dimensions that spirometry alone does not capture.

---

---

COPD — Short Case for Final Year Practicals

---

THE SETUP

"This 58-year-old gentleman has been referred to the respiratory clinic with breathlessness. Please examine his respiratory system and present your findings."

---

STEP 1: BEFORE YOU TOUCH THE PATIENT

"On general inspection, this gentleman is sitting upright in the bed / chair. He appears comfortable at rest / in mild respiratory distress. He is using accessory muscles of respiration. He has a barrel-shaped chest. There is a Venturi mask / oxygen delivery device by the bed. There are inhalers on the bedside table."

• Inhalers (COPD confirmed before you even touch him)
• Oxygen mask / flow rate and delivery device
• Sputum pot
• Nebuliser mask
• Pursed-lip breathing
• Tripod posture (hands on knees)
• Cachexia / muscle wasting

---

STEP 2: HANDS

---

STEP 3: PULSE AND RESPIRATORY RATE

• Count RR for 30 seconds: expect tachypnoea (> 20/min)
• Radial pulse: Bounding (CO2 retention causes vasodilation) or tachycardic
• If PR asked: may be irregular (AF - common comorbidity in COPD)

---

STEP 4: FACE

---

STEP 5: NECK - JVP

• Position patient at 45 degrees
• Look for the double waveform in the right internal jugular vein
• "The JVP is elevated / not elevated. An elevated JVP here would suggest cor pulmonale or right heart failure as a complication of the underlying lung disease."
• Check for hepatojugular reflux: press on RUQ for 10 seconds - JVP rises if RV failing

---

STEP 6: TRACHEA

• "The trachea is central" (tracheal deviation would suggest tension pneumothorax or large consolidation)
• Tracheal tug / descent on inspiration (Limpet sign) - suggests severe hyperinflation - the trachea moves downward with each breath

---

STEP 7: INSPECTION OF THE CHEST

"The chest is barrel-shaped with an increased antero-posterior diameter. The ribs appear more horizontal than normal. There is bilateral, symmetrical reduction in chest expansion. The accessory muscles — sternocleidomastoid and scalenes — are visibly active. There is sub-costal / intercostal recession."

• Count ribs visible on inspiration from the back (> 6 is abnormal, suggests hyperinflation)
• Look for scars (previous thoracic surgery, LVRS)
• Look for asymmetry (suggests pneumothorax, effusion, consolidation)

---

STEP 8: PALPATION

• Place both hands on the chest, thumbs parallel to the midline, fingers wrapped around the chest
• Ask patient to take a deep breath
• "Chest expansion is bilaterally and symmetrically reduced - I estimate approximately 2 cm bilaterally" (normal is 5 cm)

• Use the ulnar border of both hands simultaneously, comparing sides
• "TVF is bilaterally reduced throughout, consistent with hyperinflation attenuating sound transmission"

---

STEP 9: PERCUSSION

"Percussion note is bilaterally hyperresonant throughout, consistent with hyperinflation."

• Hyperresonance throughout = emphysema / hyperinflation
• Absent cardiac dullness at left sternal border (specificity 99% - LR+ 15 for COPD)
• Liver dullness displaced downward (pushed down by hyperinflated lungs - hepatic dullness begins > 2 intercostal spaces below the expected level)
• Diaphragmatic excursion < 2 cm (normally 4-6 cm)

---

STEP 10: AUSCULTATION

"Air entry is globally and bilaterally reduced. The expiratory phase is prolonged. There are bilateral scattered expiratory wheezes. There are early inspiratory crackles at both bases."

---

STEP 11: COMPLETE THE EXAMINATION

• Check oxygen saturation
• Check the peak flow
• Examine the cardiovascular system for cor pulmonale (JVP, RV heave, P2, oedema)
• Examine the abdomen for hepatomegaly (hepatic congestion)
• Check for ankle oedema
• Look at the observation chart and medication list
• Review the CXR and spirometry

---

STEP 12: PRESENTATION TO EXAMINER

---

"On examination of this 58-year-old gentleman, the most striking finding on general inspection was a barrel-shaped chest with use of accessory muscles and pursed-lip breathing, suggesting significant hyperinflation.

In the hands, there was peripheral cyanosis and nicotine staining, with no finger clubbing. There was a coarse flapping tremor consistent with CO2 retention. The pulse was 104 bpm and bounding.

Centrally, there was central cyanosis. The JVP was elevated at 4 cm above the sternal angle.

On examination of the chest, expansion was bilaterally reduced at approximately 2 cm. Percussion was hyperresonant throughout with absent cardiac dullness and displaced hepatic dullness. On auscultation, air entry was globally reduced with a prolonged expiratory phase, bilateral expiratory wheeze, and early inspiratory crackles at both bases.

In summary, these findings are consistent with severe COPD with features of hyperinflation, airway obstruction, CO2 retention, and cor pulmonale.

I would like to confirm this with post-bronchodilator spirometry, an arterial blood gas, ECG, and a chest X-ray."

---

WHAT THE EXAMINER WILL ASK NEXT

---

Severe COPD with acute-on-chronic type 2 respiratory failure and cor pulmonale.

---

Post-bronchodilator spirometry showing FEV1/FVC < 0.70. ABG to quantify hypoxaemia and hypercapnia. CXR for hyperinflation, flat diaphragms. ECG for P pulmonale and RV strain.

---

Hyperinflation (> 7 posterior ribs visible), flat diaphragms (most reliable sign), increased AP diameter on lateral, widened retrosternal space, paucity of peripheral vascular markings in emphysema, or increased bronchovascular markings in bronchitis.

---

GOLD grading by post-bronchodilator FEV1 % predicted (after confirming FEV1/FVC < 0.70):

---

RV hypertrophy and failure caused by pulmonary hypertension from chronic lung disease. In COPD, sustained hypoxia causes pulmonary vasoconstriction → raised pulmonary vascular resistance → RV pressure overload → eventually RV failure. Signs: raised JVP, left parasternal heave, loud P2, tricuspid regurgitation murmur, peripheral oedema.

---

CO2 retention (hypercapnia) causes peripheral vasodilation and a hyperdynamic circulation, producing a bounding, full-volume pulse. It should prompt immediate ABG to assess PaCO2 and pH.

---

COPD does not cause clubbing. Its presence would mandate active exclusion of bronchogenic carcinoma, bronchiectasis, or interstitial fibrosis - conditions that can coexist with or mimic COPD.

---

Controlled oxygen via Venturi mask targeting SpO2 88-92%, urgent ABG, nebulised salbutamol, and assess need for NIV if pH < 7.35 with hypercapnia.

---

SHORT CASE CHECKLIST (Self-Assessment)

• Spotted inhalers / oxygen at foot of bed
• Commented on general appearance (barrel chest, accessory muscles, pursed lips)
• Checked for clubbing and correctly stated its absence is expected
• Tested for asterixis
• Found central cyanosis
• Assessed JVP and commented on cor pulmonale
• Checked trachea (central) and tracheal descent
• Noted hyperresonance on percussion
• Noted absent cardiac dullness
• Noted reduced air entry + prolonged expiration + wheeze on auscultation
• Offered to complete examination (CVS, abdomen, ankle oedema, SpO2)
• Gave a structured 60-second presentation
• Named the diagnosis with a complication
• Mentioned spirometry and ABG as confirmatory investigations

---

• Ask me to do long cases, short cases, or OSCEs for any condition
• Request viva questions and model answers
• Ask about specific drugs, investigations, or mechanisms
• Request comparisons (e.g. COPD vs asthma vs cardiac failure)
• Ask me to quiz you on a topic